Iradimed Corporation (NASDAQ:IRMD) Stock Position Lifted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Iradimed Corporation (NASDAQ:IRMD - Free Report) by 189.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 66,632 shares of the medical equipment provider's stock after purchasing an additional 43,635 shares during the period. Charles Schwab Investment Management Inc. owned about 0.53% of Iradimed worth $3,351,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in IRMD. Comerica Bank increased its holdings in shares of Iradimed by 2,151.6% in the 1st quarter. Comerica Bank now owns 1,441 shares of the medical equipment provider's stock valued at $63,000 after acquiring an additional 1,377 shares during the last quarter. 1620 Investment Advisors Inc. bought a new stake in shares of Iradimed in the 2nd quarter valued at approximately $25,000. Bank of New York Mellon Corp increased its holdings in shares of Iradimed by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,971 shares of the medical equipment provider's stock valued at $2,547,000 after acquiring an additional 4,363 shares during the last quarter. Bailard Inc. bought a new stake in shares of Iradimed in the 2nd quarter valued at approximately $202,000. Finally, Shaker Investments LLC OH increased its holdings in shares of Iradimed by 1.7% in the 2nd quarter. Shaker Investments LLC OH now owns 20,605 shares of the medical equipment provider's stock valued at $905,000 after acquiring an additional 347 shares during the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.

Iradimed Stock Performance

Shares of NASDAQ IRMD traded down $1.80 during trading on Friday, reaching $52.63. The stock had a trading volume of 72,108 shares, compared to its average volume of 48,508. Iradimed Corporation has a one year low of $40.18 and a one year high of $57.95. The stock has a market cap of $666.82 million, a PE ratio of 36.05 and a beta of 0.82. The firm's 50 day moving average price is $52.58 and its two-hundred day moving average price is $48.00.

Iradimed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were paid a dividend of $0.15 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a yield of 1.14%. Iradimed's payout ratio is currently 41.10%.

Insider Buying and Selling

In related news, CFO John Glenn sold 2,500 shares of the company's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the completion of the transaction, the chief financial officer now directly owns 4,383 shares in the company, valued at $237,470.94. This represents a 36.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 37.10% of the stock is owned by company insiders.

Iradimed Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.